Adding the clinical framing, because it changes how the question reads.
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history. Results were encouraging:
- NT-proBNP: 65 pg/mL (normal, cardiac function preserved)
- Lp(a): 45 nmol/L (genetic, unchanged — expected)
- ApoB: dropped from 145 to 90 mg/dL (excellent response)
- Coronary calcium score: 0 (unchanged from baseline — reassuring)
The ApoB reduction is particularly meaningful — it's considered the best single predictor of cardiovascular risk. GLP-1 therapy seems to improve this consistently.
Dr.AddMedPHL said:I want to bring up the cardiovascular angle on cardiovascular risk.
Senior perspective on cardiovascular risk: I'm 65 years old and started this journey skeptically. My endocrinologist recommended it after years of failed interventions.
15 months later: down 53 lbs, more mobile, pain reduced, medications simplified. My quality of life has improved dramatically. I wish this existed 20 years ago.
To other older adults hesitating: the SELECT trial proved benefit in our age group. You deserve to feel good in your body regardless of age.
Dr.AddMedPHL said:I want to bring up the cardiovascular angle on cardiovascular risk.
Thank you for spelling out the reasoning rather than just the conclusion.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFrom the other side of the consultation, briefly.
NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).
From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.
Compare to established therapies:
| Intervention | NNT | Timeframe |
|---|---|---|
| Semaglutide (MACE) | 67 | 3.3 years |
| Statins primary prevention (MI) | ~100 | 5 years |
| Aspirin secondary prevention | ~77 | 2 years |
These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.